To examine the therapeutic effect of efgartigimod in a patient with cervical cancer who developed ICI-related MG-myositis overlap syndrome after receiving tislelizumab.
Approach:
Patient Data Collection: Clinical data from the patient was collected, including laboratory tests and examinations.
Efgartigimod Treatment: Efgartigimod was administered, and clinical severity was evaluated using standardized assessment scales.
Key Findings:
A 69-year-old female with cervical cancer developed bilateral ptosis, dysarthria, and limb weakness following tislelizumab therapy.
Serum creatine kinase was markedly elevated at 553.82 U/L.
After four infusions of efgartigimod (10 mg/kg), creatine kinase normalized, ADL score decreased from 10 to 1, and QMG score improved from 16 to 5.
The patient was asymptomatic at the 5 months follow-up with no need for a second treatment cycle.
Interpretation:
Limitations:
Only one case study is presented, limiting generalizability.
Further research is needed to establish broader efficacy and safety of efgartigimod in this context.
